Compare · BSX vs UFPT
BSX vs UFPT
Side-by-side comparison of Boston Scientific Corporation (BSX) and UFP Technologies Inc. (UFPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and UFPT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 34.9x UFPT ($1.87B).
- Over the past year, BSX is down 57.5% and UFPT is up 5.8% - UFPT leads by 63.3 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 7 for UFPT).
- Company
- Boston Scientific Corporation
- UFP Technologies Inc.
- Price
- $44.02-1.32%
- $241.86-5.71%
- Market cap
- $65.44B
- $1.87B
- 1M return
- -6.16%
- +4.40%
- 1Y return
- -57.53%
- +5.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1993
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest UFPT
- Amendment: SEC Form SCHEDULE 13G/A filed by UFP Technologies Inc.
- UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference
- Director Feldmann Cynthia L exercised 1,200 shares at a strike of $43.95 and sold $287,149 worth of shares (1,200 units at $239.29) (SEC Form 4)
- UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Executive Chairman Bailly R Jeffrey was granted 1,787 shares and covered exercise/tax liability with 750 shares, increasing direct ownership by 0.61% to 171,200 units (SEC Form 4)
- SVP Human Resources Stafford Ryan K was granted 1,448 shares (SEC Form 4)
- New insider Stafford Ryan K claimed no ownership of stock in the company (SEC Form 3)
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Financial Officer Lataille Ronald J was granted 4,454 shares, increasing direct ownership by 28% to 20,352 units (SEC Form 4)
- President Rock Mitchell was granted 2,895 shares, increasing direct ownership by 8% to 39,115 units (SEC Form 4)